ReviewWorld journal of gastroenterology2015
Gut microbiota and liver diseases.
Review in World journal of gastroenterology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03669835 (The Sublimated Mare Milk Supplement In Patients With Hepatitis C), which is not on this map. Cited by 84 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Sublimated Mare Milk Supplement In Patients With Hepatitis C
Who cites it
84 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Probiotics for people with hepatic encephalopathy.The Cochrane database of systematic reviews · 2017Pooled it
- Biliary Microbiota in Health and Disease: Clinical Implications in Lithiasis, Infection, and Antimicrobial Resistance.Antibiotics (Basel, Switzerland) · 2026Review
- Fungal Polysaccharides as Modulators of Molecular Pathways in Liver Health.Molecules (Basel, Switzerland) · 2025Review
- Implications of gut microbiota in hepatic and pancreatic diseases: Gut-liver-pancreas axis.World journal of hepatology · 2025Article
- Multi-omics analysis provides new insights into molecular mechanisms for waterfowl fatty liver formation.Poultry science · 2025Article
- Article
- Inorganic dietary nanoparticles in intestinal barrier function of inflammatory bowel disease: allies or adversaries?Frontiers in immunology · 2025Review
- The Role of Dietary Ingredients and Herbs in the Prevention of Non-Communicable Chronic Liver Disease.Nutrients · 2024Review
- Article
- Role of tenofovir dipivoxil in gut microbiota recovery from HBV-infection induced dysbiosis.BMC microbiology · 2024Article
- Exploring the gut microbiome: probiotics, prebiotics, synbiotics, and postbiotics as key players in human health and disease improvement.Food science and biotechnology · 2024Review
- Polyphenols from Foxtail Millet Improve Non-Alcoholic Fatty Liver Disease by Regulating Intestinal Microbiome in Mice.Foods (Basel, Switzerland) · 2024Article
- Supplementation withAnimals : an open access journal from MDPI · 2024Article
- Natural lipid nanoparticles extracted from Morus nigra L. leaves for targeted treatment of hepatocellular carcinoma via the oral route.Journal of nanobiotechnology · 2024Article
- Metabolic-associated fatty liver disease and pregnancy complications: new challenges and clinical perspectives.Therapeutic advances in endocrinology and metabolism · 2024Review
- A new target for treating intervertebral disk degeneration: gut microbes.Frontiers in microbiology · 2024Review
- Changes in intestinal flora of mice induced by rEg.P29 epitope peptide vaccines.Immunity, inflammation and disease · 2023Article
- Metabolic-Associated Fatty Liver Disease and Insulin Resistance: A Review of Complex Interlinks.Metabolites · 2023Review
- Article
- Alteration of the Gut Microbiota in Missed Abortion.Indian journal of microbiology · 2023Article
24 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Several studies revealed that gut microbiota are associated with various human diseases, e.g., metabolic diseases, allergies, gastroenterological diseases, and liver diseases. The liver can be greatly affected by changes in gut microbiota due to the entry of gut bacteria or their metabolites into the liver through the portal vein, and the liver-gut axis is important to understand the pathophysiology of several liver diseases, especially non-alcoholic fatty liver disease and hepatic encephalopathy. Moreover, gut microbiota play a significant role in the development of alcoholic liver disease and hepatocarcinogenesis. Based on these previous findings, trials using probiotics have been performed for the prevention or treatment of liver diseases. In this review, we summarize the current understanding of the changes in gut microbiota associated with various liver diseases, and we describe the therapeutic trials of probiotics for those diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.